menu
    • menu

    Company profile for Zelluna Immunotherapy

    NEW Drugs in Dev: 1
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Zelluna Immunotherapy AS is a privately owned biopharmaceutical company founded in 2016 focused on developing transformative T cell receptor (TCR) based cellular immunotherapies for the treatment of cancers. We are a dynamic and growing team that consists of highly engaged and motivated people that all share the same goal reflected in our vision: “Saving life through innovative cancer targeted cell therapies” To achieve th...
    Zelluna Immunotherapy AS is a privately owned biopharmaceutical company founded in 2016 focused on developing transformative T cell receptor (TCR) based cellular immunotherapies for the treatment of cancers. We are a dynamic and growing team that consists of highly engaged and motivated people that all share the same goal reflected in our vision: “Saving life through innovative cancer targeted cell therapies” To achieve this and provide benefit to patients and their families, we are developing TCR guided cell therapies deploying a mechanism of action that we believe has the potential to be both safer and more potent at the same time.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Zelluna ImmunotherapyNorway Flag
    Country
    Country
    Norway
    Address
    Address
    Oslo Cancer Cluster Innovation Park Ullernchausséen 64 0379 Oslo
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.zelluna.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/zelluna
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zelluna ASA: Approval And Publication Of Prospectus
    Zelluna ASA: Approval And Publication Of Prospectus

    15 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/15/3219348/0/en/Zelluna-ASA-Approval-and-publication-of-prospectus.html

    GLOBENEWSWIRE
    15 Jan 2026
    Share Share
    Zelluna Submits UK CTA for ZIMA-101 First-in-Human Trial
    Zelluna Submits UK CTA for ZIMA-101 First-in-Human Trial

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3207165/0/en/Zelluna-Reaches-Major-Milestone-and-Submits-Clinical-Trial-Application-in-the-UK-for-First-in-Human-Study-of-ZI-MA4-1-ZIMA-101-the-World-s-First-MAGE-A4-Targeting-TCR-NK-Cell-Thera.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Zelluna Finishes Initial GMP Batch Of ZI-MA4-1, TCR-NK Cell Trial
    Zelluna Finishes Initial GMP Batch Of ZI-MA4-1, TCR-NK Cell Trial

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204570/0/en/Zelluna-Completes-First-GMP-Batch-of-ZI-MA4-1-a-Novel-TCR-NK-Cell-Therapy-to-Treat-Patients-in-Upcoming-First-in-Human-Trial.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Zelluna ASA: Cancellation Of Subsequent Repair Offering
    Zelluna ASA: Cancellation Of Subsequent Repair Offering

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202086/0/en/Zelluna-ASA-Cancellation-of-subsequent-repair-offering.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    Zelluna ASA - Mandatory notification of trade
    Zelluna ASA - Mandatory notification of trade

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201845/0/en/Zelluna-ASA-Mandatory-notification-of-trade.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Zelluna ASA: New share capital registered
    Zelluna ASA: New share capital registered

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201445/0/en/Zelluna-ASA-New-share-capital-registered.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search